Forge Biologics Capacity Update February 2024: Cell & Gene

Source: Forge Biologics

Forge’s Director of Client Development, Andrew Krajewski, highlights Forge’s 200,000 square foot, custom-designed cGMP facility dedicated to AAV and plasmid manufacturing. Forge’s end-to-end development and manufacturing capabilities include research-grade production, analytical and process development, toxicology, engineering, and cGMP manufacturing, automated and semi-automated fill-finish and stability, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma